The China pharmaceutical market has come of age. With record breaking investments in innovative companies, support from the CFDA, and new product approvals pending, China has entered a new age as a global competitor in new drug development and commercialization. China remains the second largest global economy, with USD 5.3 billion+ in VC investment in the life sciences sector in 2016. There are more market entry opportunities than ever before.
ChinaBio® Group, a leading consulting and advisory partner with significant experience in China’s life science industry, has put together an insider’s list of the Top 100* pharmaceutical companies in China to make it easier for life science BD teams to scout and pursue successful cross-partnerships with China-based companies.
To meet and partner with over 900 global executives from pharma, biotech, finance and cross-border partners, register to attend ChinaBio® Partnering Forum taking place in Zhuhai, China, May 31–June 1, 2017.